OncoMatch/Clinical Trials/NCT06851247
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Is NCT06851247 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Toripalimab and Anlotinib for nasopharyngeal carcinoma.
Treatment: Toripalimab · Anlotinib · Gemcitabine · Cisplatin — In order to explore the efficacy and safety of targeted therapy and immunotherapy combined with GP chemotherapy in the treatment of high risk advanced nasopharyngeal carcinoma, the investigators design a single-arm, Phase II clinical trial targeted high-risk patients with local stage nasopharyngeal carcinoma (stage IVa: TanyN3M0/T4N0-2M0,8th AJCC/UICC staging) for Toripalimab Plus Anlotinib Combined With GP Induction Chemotherapy and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance Therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior use of anti-PD-1 antibodies
Cannot have received: anti-PD-L1 therapy
Prior use of anti-PD-L1 antibodies
Cannot have received: anti-PD-L2 therapy
Prior use of anti-PD-L2 antibodies
Cannot have received: anti-CTLA-4 therapy
Prior use of anti-CTLA-4 antibodies (or any other antibody that acts on the T-cell co-stimulation or checkpoint pathway)
Lab requirements
Blood counts
Hemoglobin (HGB) ≥90 g/L, white blood cells (WBC) ≥4.0×10^9 /L, platelets (PLT) ≥100×10^9 /L
Kidney function
serum creatinine <1.5×ULN
Liver function
ALT and AST < 2.5 times the upper limit of normal (ULN), total bilirubin <2.0×ULN
Cardiac function
no serious dysfunction of heart
Hemoglobin (HGB) ≥90 g/L, white blood cells (WBC) ≥4.0×10^9 /L, platelets (PLT) ≥100×10^9 /L. Liver function: ALT and AST< 2.5 times the upper limit of normal (ULN), total bilirubin <2.0×ULN. Renal function: serum creatinine <1.5×ULN. no serious dysfunction of heart, lung, liver, kidney and other vital organs.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify